Global Wealth Management Investment Advisory’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Global Wealth Management Investment Advisory’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-12	Closed	-$9	–	473
2023 Q4	$9	Hold	12	–	–	﹤0.01%	474
2023 Q3	$10	Hold	12	–	–	﹤0.01%	476
2023 Q2	$22	Buy	+12	New	+$40	﹤0.01%	483
2022 Q3	–	Sell	-13	Closed	–	–	516
2022 Q2	$0	Hold	13	–	–	﹤0.01%	550
2022 Q1	$0	Hold	13	–	–	﹤0.01%	541
2021 Q4	$1K	Hold	13	–	–	﹤0.01%	444
2021 Q3	$1K	Hold	13	–	–	﹤0.01%	455
2021 Q2	$1K	Hold	13	–	–	﹤0.01%	426
2021 Q1	$2K	Hold	13	–	–	﹤0.01%	430
2020 Q4	$2K	Hold	13	–	–	﹤0.01%	414
2020 Q3	$2K	Buy	+13	New	+$2.12K	﹤0.01%	404

Other funds holding NBSE

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

CMU

Carnegie Mellon University Pittsburgh, Pennsylvania $64.3M AUM 35.71% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

CSS

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

Global Wealth Management Investment Advisory's NBSE Position: Q1 2024 in Review

Global Wealth Management Investment Advisory sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q1 2024, closing a stake of 12 shares — an estimated $9 sold.

Global Wealth Management Investment Advisory first reported a position in NBSE in Q3 2020 and held it in 11 quarters. The position peaked at $2K in Q1 2021. 19 funds tracked by Wall St. Rank hold NBSE as of Q1 2024.

Global Wealth Management Investment Advisory reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Global Wealth Management Investment Advisory sold 12 NeuBase Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $9.
Global Wealth Management Investment Advisory first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q3 2020 and held it in 11 quarters.
Global Wealth Management Investment Advisory's NeuBase Therapeutics, Inc. Common Stock position peaked at $2K in Q1 2021.
19 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Global Wealth Management Investment Advisory's 13F filing for Q1 2024, filed 10 May 2024.